2.73
前日終値:
$2.93
開ける:
$2.92
24時間の取引高:
324.04K
Relative Volume:
1.88
時価総額:
$71.65M
収益:
-
当期純損益:
$-94.11M
株価収益率:
-0.4542
EPS:
-6.01
ネットキャッシュフロー:
$-86.06M
1週間 パフォーマンス:
-20.41%
1か月 パフォーマンス:
-46.47%
6か月 パフォーマンス:
-66.95%
1年 パフォーマンス:
-75.93%
Adverum Biotechnologies Inc Stock (ADVM) Company Profile
名前
Adverum Biotechnologies Inc
セクター
電話
(650) 649-1004
住所
100 CARDINAL WAY, REDWOOD CITY, CA
ADVM を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
ADVM
Adverum Biotechnologies Inc
|
2.73 | 71.65M | 0 | -94.11M | -86.06M | -6.01 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-06-25 | 開始されました | Oppenheimer | Outperform |
2024-04-30 | 開始されました | H.C. Wainwright | Buy |
2022-07-07 | アップグレード | Truist | Hold → Buy |
2021-07-23 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
2021-05-03 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
2021-04-29 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
2021-04-29 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
2021-04-29 | ダウングレード | Truist | Buy → Hold |
2020-12-16 | 開始されました | UBS | Neutral |
2020-11-12 | アップグレード | Raymond James | Underperform → Mkt Perform |
2020-06-26 | ダウングレード | Raymond James | Mkt Perform → Underperform |
2020-05-13 | 開始されました | RBC Capital Mkts | Outperform |
2020-05-05 | アップグレード | SunTrust | Hold → Buy |
2020-04-28 | 開始されました | Goldman | Buy |
2020-03-16 | 開始されました | SVB Leerink | Outperform |
2020-02-10 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
2020-02-10 | アップグレード | Chardan Capital Markets | Neutral → Buy |
2019-10-15 | 繰り返されました | Chardan Capital Markets | Neutral |
2019-09-13 | 繰り返されました | Chardan Capital Markets | Neutral |
2019-06-14 | 再開されました | Raymond James | Mkt Perform |
2018-11-02 | ダウングレード | Raymond James | Outperform → Mkt Perform |
2018-11-02 | ダウングレード | SunTrust | Buy → Hold |
2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
2018-08-30 | 開始されました | SunTrust | Buy |
2018-02-15 | 再開されました | Piper Jaffray | Overweight |
2017-10-12 | 開始されました | Raymond James | Outperform |
すべてを表示
Adverum Biotechnologies Inc (ADVM) 最新ニュース
Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Stockholders to Inquire about Securities Investigation - markets.businessinsider.com
Truist Removes $40 Price Target on Adverum Biotechnologies, Cites Share Volatility, Keeps Buy Rating - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Investors to Inquire about Securities Investigation - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Investors to Reach Out - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Stockholders to Reach Out - markets.businessinsider.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - GlobeNewswire Inc.
Intuit To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biotechnologies, Inc. (ADVM) And Encourages Stockholders to Connect - markets.businessinsider.com
Press Release Distribution & PR Platform - ACCESS Newswire
RBC Cuts Price Target on Adverum Biotechnologies to $5 From $10, Keeps Sector Perform, Speculative Risk - marketscreener.com
Adverum Biotechnologies Reports 2024 Financial Results and Pipeline Progress - TipRanks
Adverum Biotechnologies: Q4 Earnings Snapshot - CT Insider
Adverum Biotechnologies, Inc. (ADVM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
ADVM Investors Have Opportunity to Join Adverum Biotechnologies, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire
Adverum Biotechnologies Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Adverum Biotechnologies Reports Fourth Quarter and Full - GlobeNewswire
Adverum Advances Gene Therapy Pipeline Despite Wider Losses: Key Q4 Developments Revealed - Stock Titan
Adverum Biotechnologies, Inc. SEC 10-K Report - TradingView
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc.ADVM - PR Newswire
Avalanche Biotechnologies Announces Executive Changes - MarketScreener
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Adverum Biotech Grants 30,000 Share Options to New Executive: Key Details - Stock Titan
Adverum biotechnologies sees $147k stock purchase by major shareholder - Investing.com Australia
Adverum Biotechnologies, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your RightsADVM - ACCESS Newswire
Adverum Biotechnologies Inc expected to post a loss of $1.36 a shareEarnings Preview - TradingView
Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference - The Manila Times
Exclusive: Adverum Gene Therapy Updates Coming at Major Ophthalmology Conference - Stock Titan
Adverum biotechnologies investor Leonard Braden Michael buys $188,930 in stock By Investing.com - Investing.com Australia
Adverum biotechnologies sees insider purchase totaling $587,574 By Investing.com - Investing.com Canada
Adverum biotechnologies sees insider purchase totaling $587,574 - Investing.com
Adverum Biotechnologies (ADVM) to Release Earnings on Monday - Defense World
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.
Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD - Marketscreener.com
Adverum launches phase 3 trial for wet AMD gene therapy By Investing.com - Investing.com UK
Can This One-Time Gene Therapy Revolutionize Wet AMD Treatment? Adverum's Phase 3 Trial Begins - StockTitan
Adverum Biotechnologies initiates ARTEMIS study - TipRanks
Adverum biotechnologies sees $1.44 million stock purchase by major shareholder - Investing.com Australia
How Adverum is Attracting Talent: New Employees Receive $186,000 in Equity Grants - StockTitan
Adverum Biotechnologies Inc (ADVM) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):